AMEX · NRXS
NeurAxis, Inc.
$7.55-$0.02 (-0.26%)
NeurAxis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.08% below the high.
Loading market information…
NASDAQ · NERV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Minerva Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Minerva Neurosciences, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Minerva Neurosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Feb 25, 2025 |
| -$0.56+46.67% vs estimate |
| $42.22K |
| Q3 2024 | Nov 5, 2024 | $2.97+394.06% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $10.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.55-$0.02 (-0.26%)
NeurAxis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.08% below the high.
$15.41-$0.58 (-3.63%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.31% below the high.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
$3.16-$0.02 (-0.63%)
TAO Synergies Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.89% below the high.
$0.38-$0.03 (-7.1%)
Klotho Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.26% below the high.
$1.26-$1.84 (-59.35%)
Sonnet BioTherapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.47% below the high.
$4.40+$0.45 (+11.39%)
CollPlant Biotechnologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.79% below the high.
$0.93-$0.08 (-8.04%)
Exicure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.14% below the high.
